 |
|
|
| |
Phase 3b Studies (5 Years post-treatment) to Assess Long-Term Clinical Outcomes in HCV GT1-Infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Emily O Dumas, Jeff rey Enejosa, Greg Ball, Yiran B Hu, Melannie Co, Rajvineeth Kumar Pothacamury, Yan Liu,
Nancy Shulman, Thomas Podsadecki
1AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
